Skip to main content

Table 1 Baseline Characteristics by Stage (Discovery/Validation Cohort)

From: Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa

Characteristics Stage 1 (discovery cohort) Stage 2 (validation cohort)
PAG (N = 52) AG (N = 42) Total (N = 94) PAG (N = 65) AG (N = 30) Total (N = 95)
Mean age (min–max), years 62.5 (28–77) 66.8 (54–76) 64.4 (28–77) 64.7 (40–83) 63.3 (44–80) 64.3 (40–83)
Sex, n (%)
 Female 19 (36.5) 23 (54.8) 42 (44.7) 26 (40.0) 16 (53.3) 42 (44.2)
 Male 33 (63.5) 19 (45.2) 52 (55.3) 39 (60.0) 14 (46.7) 53 (55.8)
Race, n (%)
 White 47 (90.4) 33 (78.6) 80 (85.1) 58 (89.2) 24 (80.0) 82 (86.3)
 Black or African American 3 (5.8) 7 (16.7) 10 (10.6) 4 (6.2) 1 (3.3) 5 (5.3)
 Asian 0 (0.0) 1 (2.4) 1 (1.1) 2 (3.1) 3 (10.0) 5 (5.3)
 Multiple 0 (0.0) 1 (2.4) 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0)
 American Indian or Alaska Native 1 (1.9) 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0) 0 (0,0)
 Native Hawaiian or Other Pacific Islander 1 (1.9) 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0)
 Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 2 (2.1)
Primary tumor location (pancreas), n (%)
 Body 26 (50.0) 16 (38.1) 42 (44.7) 26 (40.0) 12 (40.0) 38 (40.0)
 Head 16 (30.8) 17 (40.5) 33 (35.1) 29 (44.6) 16 (53.3) 45 (47.4)
 Tail 10 (19.2) 9 (21.4) 19 (20.2) 10 (15.4) 2 (6.7) 12 (12.6)
Tumor biopsy site, n (%)
 Liver 40 (76.9) 23 (54.8) 63 (67.0) 39 (60.0) 18 (60.0) 57 (60.0)
 Pancreas 6 (11.5) 9 (21.4) 15 (16.0) 10 (15.4) 7 (23.3) 17 (17.9)
 Lung 1 (1.9) 2 (4.8) 3 (3.2) 2 (3.1) 1 (3.3) 3 (3.2)
 Duodenum 1 (1.9) 1 (2.4) 2 (2.1) 2 (3.1) 0 (0.0) 2 (2.1)
 Omentum 1 (1.9) 1 (2.4) 2 (2.1) 1 (1.5) 0 (0.0) 1 (1.1)
 Lymph node 1 (1.9) 0 (0.0) 1 (1.1) 1 (1.5) 0 (0.0) 1 (1.1)
 Abdomen 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.1)
 Abdominal cavity 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.1)
 Ampulla 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.1)
 Peritoneum 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.1)
 Papilla 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.3) 1 (1.1)
 History of diabetes, n (%) 18 (34.6) 18 (42.9) 36 (38.3) 19 (29.2) 13 (43.3) 32 (33.7)
C3M
 Mean 11.0 11.2 11.1 8.8 8.8 8.8
 Range 15.7 28.5 28.5 13.0 9.5 13.2
 Below LLOQ (< 1.9 ng/mL), No. 0 0 0 0 0 0
 Above ULOQ (> 54.2 ng/mL), No. 0 0 0 0 0 0
PRO-C3
 Mean 32.2 35.7 33.7 27.8 24.1 26.7
 Range 353.3 159.9 353.3 183.6 97.6 183.6
 Below LLOQ (< 4 ng/mL), No. 0 0 0 0 0 0
 Above ULOQ (> 107.6 ng/mL), No. 1 4 5 1 0 1
C3M/PRO-C3 ratio
 Mean 0.68 0.57 0.63 0.56 0.58 0.56
 Range 1.73 2.29 2.29 2.13 1.74 2.13
  1. Table shows demographics and clinical characteristics of patients for whom baseline plasma samples were available
  2. Where range is provided as a single number, it represents the difference between the lowest and highest value
  3. LLOQ: lower limit of quantification; ULOQ: upper limit of quantification